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Abstract Enantiomeric complexes of formula [PtCl2L2]
[L2 is (R)-(?)-BINAP and (S)-(-)-BINAP, where BIN-
AP is 2,20-bis(diphenylphosphane)-1,10-binaphthyl, and
(R)-(?)-DABN and (S)-(-)-DABN, where DABN is 1,10-
binaphthyl-2,20-diamine], were tested for their cytotoxic
activity against three cancer cell lines and for their ability
to bind to the human telomeric sequence folded in the
G-quadruplex structure. Similar experiments were carried
out on prototypal complexes cisplatin and cis-[PtCl2(PPh3)2]
for comparison. Platinum complexes containing phosphanes
proved less cytotoxic to cancer cell lines and less likely to
interact with the nucleobases of the G-quadruplex than those
containing amines; in both cases the S-(-) isomer was
more active than the R-(?) counterpart. More specifically,
whereas all the platinum complexes were able to platinate the
G-quadruplex structure from the human telomeric repeat, the
extent and sites of platination depended on the nature of the
ligands. Complexes containing (bulky) phosphanes inter-
acted only with the adenines of the loops, whereas those
containing the less sterically demanding amines interacted
with adenines and some guanines of the G-quartet.
Keywords Platinum complexes  Phosphanes and
amines  DNA quadruplex  Telomere  Cytotoxicity
Introduction
Today, more than four decades after the serendipitous
discovery of its antitumor activity [1, 2], the metallodrug
cisplatin has earned a key place in the systemic treatment
of cancers, especially in polychemotherapeutic regimes [3].
However, its severe side effects and possible failure in
subsequent treatment owing to drug resistance have resul-
ted in a concerted effort to develop new platinum com-
plexes with improved pharmacological properties. To this
aim, thousands of analogues have been synthesized (by
varying the carrier and/or leaving groups) and tested, but
only about 35 compounds have entered clinical trials so far.
Carboplatin and oxaliplatin are in routine clinical use
worldwide, whereas nedaplatin, lobaplatin, and heptaplatin
have achieved regional approval only in Japan, China, and
South Korea, respectively [4].
Structure–activity relationship studies by Cleare and
Hoeschele [5–7] have demonstrated that effective plati-
num-based cytotoxic agents should possess a square-planar
Pt(II) structure with two chlorides or carboxylates as
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leaving groups and two amines as carrier ligands in cis
configuration. Another variant would consist of phospanes
rather than amines.
The chemistry of platinum–phosphane compounds is
probably one of the most intensely studied chemistries in
inorganic chemistry [8]; the number and diversity of
phosphanes synthesized has increased rapidly since the
1960s for the preparation of new and ever-more-efficient
homogeneous catalysts [9].
The in vivo antitumor activity of the PPh3 analogue of
cisplatin, namely, cis-[PtCl2(PPh3)2], and of a series of
similar platinum–phosphane complexes has been studied
against lymphoid leukemia in mice, but with disappoint-
ing results (i.e., median survival time T/C \ 125%) [10].
A number of factors may have contributed to this poor
outcome: (1) tertiary phosphanes were generally used in
aqueous media owing to the easy hydrolysis of P–H
bonds; however, the presence of the N–H linkage has
been shown to be crucial for the formation of cytotoxic
adducts by establishing hydrogen bonds between cisplatin-
like complexes and the DNA phosphate backbone; (2) the
low water solubility of substituted phosphanes unfavor-
ably affects drug administration and biodistribution; (3)
the steric hindrance and trans-labilizing effect of substi-
tuted phosphanes is higher than that of amines and may
cause decreased stability of the Pt–G adducts in DNA.
The poor antitumor activity of the phosphane-containing
complexes initially studied [10] probably discouraged
further research into the biological applications of these
compounds.
The aim of the present work was to compare the per-
formance of a panel of platinum-containing complexes
(Fig. 1) of the general formula [PtCl2L2] containing large,
chiral, aromatic ligands [L2 is (R)-(?)-BINAP, 1R, and
(S)-(-)-BINAP, 1S, where BINAP is 2,20-bis(diphe-
nylphosphane)-1,10-binaphthyl), (R)-(?)-DABN, 2R, and
(S)-(-)-DABN, 2S, where DABN is 1,10-binaphthyl-2,20-
diamine] in terms of their ability to bind DNA nucleobases
and to elicit biological effects.
Two parameters were considered in assessing the
biological activity of the complexes: their ability to bind to
G-quadruplexes in telomeres and to cross-link them, and
their overall cytotoxicity on selected human tumor cell
lines, namely, A2780 ovarian carcinoma and its cisplatin-
resistant form A2780Cp8 and colon adenocarcinoma
HCT116. It is well known that the cytotoxic activity of
Pt(II) complexes is mainly due to their ability to coordin-
atively link nuclear DNA.
Telomeres are specialized repeats of G-rich DNA
sequences (TTAGGG, in humans) that cap the end of
linear eukaryotic chromosomes and prevent their degra-
dation [11]. In normal cells, telomeres shorten by 50–
200 bp for each round of replication because of the
incomplete end replication of DNA [12]. A limit of
telomere length is then reached and the cells undergo
senescence and/or apoptosis.
Fig. 1 Structure of the
complexes under investigation,
with the general formula
[PtCl2L2]: L2 is 2 9 NH3,
cisplatin; 2 9 PPh3, cis-
[PtCl2(PPh3)2]; (R)-(?)-BINAP,
1R; (S)-(-)-BINAP, 1S; (R)-
(?)-DABN, 2R, and (S)-(-)-
DABN, 2S, where
BINAP is 2,20-
bis(diphenylphosphane)-1,10-
binaphthyl and DABN is 1,10-
binaphthyl-2,20-diamine
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Telomerase (the enzyme involved in maintaining telo-
mere length) is usually inactivated in differentiated cells,
but it is reactivated in approximately 85–90% of human
tumors. It adds telomeric DNA repeats at the 30 ends of
telomeres, compensating for the loss of telomeres at each
round of replication and thus contributing to the malignant
transformation [13].
The G-rich 30 extremity of telomeres protrudes as a
single strand of about 200 bases. In the presence of
monovalent cations, this extremity has been shown to
fold, in vitro, into four-stranded DNA structures, called
G-quadruplexes, which consist of stacks of G-quartets
(four guanines linked by Hoogsteen hydrogen bonds)
[11, 14, 15]. Since telomerase requires an unfolded sin-
gle-stranded substrate, G-quadruplex conformations hin-
der telomerase activity. Therefore, any compound that
stabilizes these G-quadruplexes could conceivably be
effective as a telomerase inhibitor and, consequently, as
an antitumor agent [16, 17]. It has also been shown that
G-quadruplex stabilizers can deprotect telomeres by
preventing the binding of essential telomeric proteins;
this leads to cellular death, independently of telomerase
inhibition [18]. The G-rich telomeres represent an ideal
target for platinum complexes [19, 20]. Indeed, the
telomere length regulation and telomerase-inhibiting
properties of cisplatin and its congeners have already
been studied [21–27].
Redon et al. [28, 29] and Ourliac-Garnier et al. [30, 31]
demonstrated the ability of G-quadruplex structures to
form platinum adducts. Mono- and bifunctional platinum
complexes were shown to bind free adenines (preferen-
tially A7 and A19) in the loop regions. Unexpectedly, these
complexes also proved to bind the four guanines of one
external G-quartet of the antiparallel G-quadruplex struc-
ture of the human telomeric sequence (G2, G10, G14,
G22), suggesting a transient disruption of the hydrogen
bonds of this G-quartet. Such cross-linking would prevent
the unfolding of the G-quadruplex, and, hence, inhibit
telomerase activity. In contrast, Heringova et al. [32]
hypothesized that the binding of cisplatin to its usual N7-G
DNA binding site might interfere with the Hoogsteen
hydrogen bonding that stabilizes G-quadruplexes; this
would either inhibit quadruplex formation or destabilize
the quadruplex structure.
A platinum–quinacridine-based compound was found to
interact with DNA quadruplexes via a dual mechanism:
nucleobase coordination by the electrophilic platinum
moiety and p–p interaction (stacking) between the large
planar aromatic system and the G-quartet on the external
surface of the G-quadruplex [33, 34]. Because they contain
aromatic ligands, complexes 1R, 1S, 2R, and 2S might also
act via this dual mechanism.
Materials and methods
Reagents
All chemicals, including cisplatin and cis-[PtCl2(PPh3)2]
(Aldrich), were of analytical grade and used without further
purification. Milli-Q-grade water (18 MX cm) was used for
the preparation of aqueous solutions.
Physical measurements
Elemental analyses for all the compounds were performed
routinely in our laboratories and the experimental values
corresponded to within ±0.4% of calculated values.
The NMR spectra were measured with a JEOL Eclipse
Plus spectrometer operating at 400 MHz (1H), 100.5 MHz
(13C), and 85.9 MHz (195Pt). 1H NMR and 13C NMR
chemical shifts were reported in parts per million refer-
enced to residual solvent proton resonances. 195Pt NMR
spectra were recorded in CDCl3 or N,N-dimethylformam-
ide-d7 (DMF-d7), using a solution of K2[PtCl4] in aqueous
KCl as the external reference. The shift for K2[PtCl4] was
adjusted to -1,628 ppm with respect to Na2[PtCl6]
(d = 0 ppm).
Electrospray mass spectra were obtained using a Mi-
cromass ZMD mass spectrometer. Typically, a dilute
solution of compound in 0.1:99.9 DMF/methanol or
CH3CN was delivered directly to the spectrometer source
at 0.01 mL min-1, using a Hamilton microsyringe con-
trolled by a single-syringe infusion pump. The nebulizer
tip operated at 3,000–3,500 V and 150 C, with nitrogen
used both as a drying and as a nebulizing gas. The cone
voltage was 30 V for the characterization of the com-
plexes and 15 V for the study of the aquation reactions.
Quasimolecular ion peaks [M?H]? and peaks of sodi-
ated species [M?Na]? were assigned on the basis of the
m/z values and of the simulated isotope distribution
patterns.
Rotatory power measurements were performed with a
JASCO P-2000 equipped with an intelligent remote module
(6940-J033A), a Peltier temperature controller (PTC-203),
and a tungsten–halogen lamp at 589 nm. The measure-
ments were carried out at 25 C with 2% solutions of
DABN ligands and complexes in tetrahydrofuran (THF),
and of BINAP ligands and complexes in CH2Cl2. Con-
ductivity measurements were performed using an Orion
120 conductivity meter in dimethyl sulfoxide (DMSO) at
25 and 37 ± 0.1 C using a thermostatic circulating bath to
keep the temperature of the sample constant. The analyses
were carried out on freshly prepared solutions of the
complexes in DMSO (1 mM) by measuring the molar
conductivity at regular time intervals. The UV–vis spectra
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were recorded in the wavelength range from 200 to 800 nm
with a JASCO V550 UV–vis spectrophotometer equipped
with a deuterium lamp and a halogen lamp.
Synthesis of platinum complexes 1R, 1S, 2R, and 2S
Synthesis of 1R
Complex 1R was synthesized according to published pro-
cedures [35–37]. 1H NMR (CDCl3): 7.80 (4H, m, H12),
7.60 (4H, br, H12
0), 7.56 (2H, d, 3J = 8.06 Hz, H4 or H7),
7.50 (2H, d, 3J = 8.79 Hz, H9), 7.40–7.44 (6H, m,
H13 ? H14), 7.33–7.37 (4H, m, H10 ? H5 or H6), 7.11 (2H,
m, H5 or H6), 6.82 (2H, m, H14
0), 6.74 (2H, d,
3J = 8.06 Hz, H4 or H7), 6.66 (4H, m, H13
0) ppm; 13C
NMR (CDCl3): 138.76 (C2 or C3), 135.59 (C12), 134.82
(C12
0), 133.88 (C2 or C3), 133.06 (C8), 130.43 (C140),
131.05 (C14), 129.06 (C9), 128.14 (C5 or C6), 128.05 (C10),
127.71 (C4 or C7), 127.62 (C4 or C7), 127.54 (C13), 127.31
(C13
0), 126.67 (C5 or C6), 122.41–121.69 (C11, C110, C1)
ppm; 31P{1H} NMR (CDCl3): 10.50 ppm (satellite bands
at -0.86 and 21.81 ppm, JPPt = 3,670 Hz);
195Pt NMR
(CDCl3): -4,223 (t, JPPt = 3,670 Hz) ppm. Electrospray
ionization mass spectrometry (ESI–MS) (CH3CN): 852.13
(88.88%), 853.13 (100%), 854.13 (58.70%), 855.13
(45.34%), 856.13 (16.99%) calcd for C44H32ClP2Pt; found:
852.18 (89.00%), 853.20 (100%), 854.32 (58.52%), 855.30
(45.27%), 856.13 (17.15%) [M–Cl]?. [a]D
25 (CH2Cl2):
?383 (ligand: ?124).
Synthesis of 1S
Complex 1S was synthesized according to published
procedures [35–37]. 1H NMR (CDCl3): 7.80 (4H, m,
H12), 7.60 (4H, br, H12
0), 7.56 (2H, d, 3J = 8.06 Hz, H4
or H7), 7.50 (2H, d,
3J = 8.79 Hz, H9), 7.40-7.44 (6H,
m, H13 ? H14), 7.33–7.37 (4H, m, H10 ? H5 or H6),
7.11 (2H, m, H5 or H6), 6.82 (2H, m, H14
0), 6.74 (2H, d,
3J = 8.06 Hz, H4 or H7), 6.66 (4H, m, H13
0) ppm; 13C
NMR (CDCl3): 138.76 (C2 or C3), 135.59 (C12), 134.82
(C12
0), 133.88 (C2 or C3), 133.06 (C8), 130.43 (C140),
131.05 (C14), 129.06 (C9), 128.14 (C5 or C6), 128.05
(C10), 127.71 (C4 or C7), 127.62 (C4 or C7), 127.54
(C13), 127.31 (C13
0), 126.67 (C5 or C6), 122.41–121.69
(C11, C11
0, C1) ppm;
31P{1H} NMR (CDCl3): 10.50 ppm
(satellite bands at -0.86 and 21.81 ppm, JPPt =
3,670 Hz); 195Pt NMR (CDCl3): -4,223 (t, JPPt =
3,670 Hz) ppm. ESI–MS (CH3CN): 852.13 (88.88%),
853.13 (100%), 854.13 (58.70%), 855.13 (45.34%),
856.13 (16.99%) calcd for C44H32ClP2Pt; found: 852.20
(89.06%), 853.22 (100%), 854.18 (58.30%), 855.29
(45.85%), 856.15 (16.81%) [M–Cl]?. [a]D
25 (CH2Cl2):
-383 (ligand: -124).
Synthesis of 2R
Complex 2R was synthesized directly from K2PtCl4 in
DMF. Namely, 150 mg (0.36 mmol) of K2PtCl4 was dis-
solved in 10 ml of DMF at 70 C in the dark; 102 mg of
(R)-(?)-DABN (0.36 mmol) was added to the solution and
the mixture was stirred at 40 C in the dark overnight. The
resulting yellow solution was filtrated to remove the pre-
cipitated KCl, and the solvent was then removed under
reduced pressure. The crude product was precipitated with
water, leading to a yellow powder that was washed with
cold water, a mixture of 10:90 methanol/diethyl ether, and
diethyl ether and then dried under a vacuum (yield 154 mg;
78%).
1H NMR (DMF-d7): 8.18 (2H, d,
3J = 8.42 Hz, H10),
8.10 (2H, d, 3J = 8.42 Hz, H9), 7.86 (2H, d,
3J = 8.60 Hz,
H4 or H7), 7.52 (2H, m, H5 or H6), 7.47 (2H, br d,
J = 11.16 Hz, NH2), 7.33 (2H, m, H5 or H6), 6.97 (2H, d,
3J = 8.60 Hz, H4 or H7), 6.85 (2H, br d, J = 11.16 Hz,
NH2) ppm;
13C{1H} NMR (DMF-d7): 139.33 (C1), 134.03
(C3), 132.05 (C8), 130.37 (C10), 128.59 (C9), 126.88 (C5 or
C6), 125.64 (C4 or C7), 125.29 (C5 or C6), 121.93 (C2),
121.46 (C4 or C7) ppm;
195Pt NMR (DMF-d7):
-1,866 ppm. ESI–MS (0.1:99.9 DMF/methanol): 514.06
(93.20%), 515.06 (100%), 516.06 (45.03%), 517.06
(42.19%), 518.07 (8.75%) calcd for C20H16ClN2Pt; found:
514.48 (92.02%), 515.33 (100%), 516.12 (43.92%), 517.45
(42.12%), 518.18 (9.14%) [M–Cl]?. [a]D
25 (THF): ?330
(ligand: ?144).
Synthesis of 2S
Complex 2S was synthesized directly from K2PtCl4 in
DMF. Namely, 137 mg (0.33 mmol) of K2PtCl4 was dis-
solved in 10 ml of DMF at 70 C in the dark; 94 mg of (S)-
(-)-DABN (0.33 mmol) was added to the solution and the
mixture was stirred at 40 C in the dark overnight. The
resulting yellow solution was filtrated to remove the pre-
cipitated KCl, and the solvent was then removed under
reduced pressure. The crude product was precipitated with
water, yielding a yellow powder that was washed with cold
water, a mixture of 10: 90 methanol/diethyl ether, and
diethyl ether and then dried under a vacuum (yield 130 mg;
72%).
1H NMR (DMF-d7): 8.18 (2H, d,
3J = 8.42 Hz, H10),
8.10 (2H, d, 3J = 8.42 Hz, H9), 7.86 (2H, d,
3J = 8.60 Hz,
H4 or H7), 7.52 (2H, m, H5 or H6), 7.47 (2H, br d,
J = 11.16 Hz, NH2), 7.33 (2H, m, H5 or H6), 6.97 (2H, d,
3J = 8.60 Hz, H4 or H7), 6.85 (2H, br d, J = 11.16 Hz,
NH2) ppm;
13C{1H} NMR (DMF-d7): 139.33 (C1), 134.03
(C3), 132.05 (C8), 130.37 (C10), 128.59 (C9), 126.88 (C5 or
C6), 125.64 (C4 or C7), 125.29 (C5 or C6), 121.93 (C2),
121.46 (C4 or C7) ppm;
195Pt NMR (DMF-d7):
844 J Biol Inorg Chem (2010) 15:841–850
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-1,866 ppm. ESI–MS (0.1:99.9 DMF/methanol): 514.06
(93.20%), 515.06 (100%), 516.06 (45.03%), 517.06
(42.19%), 518.07 (8.75%) calcd for C20H16ClN2Pt; found:
514.52 (92.44%), 515.12 (100%), 516.32 (44.22%), 517.24
(42.01%), 518.23 (9.25%) [M–Cl]?. [a]D
25 (THF): -330
(ligand: -144).
Cytotoxicity tests
Three human tumor cell lines were used for the present
study: A2780 (ovarian carcinoma) and HCT116 (colon
adenocarcinoma) were obtained from the American Type
Culture Collection (Manassas, VA, USA); A2780Cp8
cells (so-called because of their ability to grow in medium
containing 8 lM cisplatin) were developed by chronic
exposure of the parent cisplatin-sensitive line to increas-
ing concentrations of cisplatin, and were obtained from R.
Ozols (Fox Chase Cancer Center, Philadelphia, PA, USA).
A2780Cp8 cells differ from the parental cell line in a
number of features that contribute to the resistant phe-
notype, including alterations in mismatch and nucleotide
excision DNA repair systems and increased glutathione
levels. The three cell lines were maintained in RPMI-1640
(Sigma, Italy) supplemented with 10% fetal calf serum
(Celbio, Italy), 2 mM L-glutamine, and a 1% streptomy-
cin/penicillin antibiotic mixture (Sigma, Italy) under
standard culture conditions (95% O2/5% CO2 at 37 C
in a humidified atmosphere). Cell survival following
exposure to platinum complexes was evaluated using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay, based on the reduction of MTT by
living cells [38]. Briefly, 1 9 103 cells per well were
plated onto 96-well sterile plates and allowed to attach
and grow for 24 h. Platinum complexes were dissolved in
DMSO (cisplatin and phosphane complexes) or in ethanol
(DABN complexes) to obtain 10 mM stock solutions
that were diluted with complete medium for cell treat-
ment. The final range of platinum concentrations was
10–500 lM; the cosolvent concentration never exceeded
0.1%. After 3 days, MTT was added to each well (final
concentration 0.4 mg mL-1) and plates were incubated
for 3 h at 37 C. Cell viability was determined by mea-
suring the absorbance (k = 570 nm) in individual wells,
using a universal microplate reader (Bio-Tek Instruments,
Winooski, VT, USA). The cytotoxic effects of platinum
complexes were quantitated by calculating the drug con-
centration inhibiting tumor cell growth by 50% (IC50),
based on nonlinear regression analysis of dose–response
data, performed using the Calcusyn program (Biosoft,
Cambridge, UK).
G-quadruplex
50-end 32P-radiolabeled AG3(T2AG3)3 (22AG) was mixed
with 100 lM nonradiolabeled material in 50 mM NaClO4
or KClO4 for 5 min at 90 C and allowed to reach room
temperature in 2 h to induce the formation of the quadru-
plex structure. It was then incubated with 300 lM platinum
complex (cis-[PtCl2(PPh3)2], 1R, 1S, 2R, or 2S). The
reactions were run for 16 h at 37 C. The platinated oli-
gonucleotides were separated using 20% polyacrylamide
denaturing gel electrophoresis and then isolated from the
gels. The platination sites were determined by means of
biochemical methods using 30-exonuclease digestion [29,
30, 34]. The kinetics of platination using intramolecular
competition experiments were performed with 2R as
described elsewhere [31, 39]. The products of platination at
the 50-end 32P-radiolabeled 35mer containing 22AG and at
the 50-end 32P-radiolabeled 13mer containing the GG
sequence were quantified after separation by gel electro-
phoresis using a Storm 960 phosphorimager (Molecular
Dynamics, Amersham Bioscience, France).
Results and discussion
Platinum complexes
Complexes 1R and 1S were synthesized by reacting stoi-
chiometric quantities of [PtCl2(g
4-1,3-cyclooctadiene)]
[35] and phosphane in CH2Cl2 according to published
procedures [36, 37]. Complexes 2R and 2S were obtained
by directly reacting K2[PtCl4] with the corresponding
diamine [40]. All the complexes were characterized by
ESI–MS, reversed-phase high-performance liquid chro-
matography, UV–vis spectroscopy, and multinuclear NMR
spectroscopy. In particular, 1H and 13C NMR signals of the
complexes were assigned using one- and two-dimensional
homonuclear and heteronuclear techniques such as
1H,13C{1H} distortionless enhancement by polarization
transfer with a final proton pulse angle of 135, 1H–1H
correlation spectroscopy, 1H–13C heteronuclear correla-
tion spectroscopy, and 1H–31P heteronuclear correlation
spectroscopy.
The performance of complex 1S as a catalyst has
already been studied by Kolla´r et al. [41], who described its
1H NMR temperature-dependent behavior. Other NMR
studies on similar complexes have been reported [42–49].
Our data confirm and complement those studies. In par-
ticular, it should be noted that for complexes 1R and 1S,
the protons on the two different phenyl rings on the same
J Biol Inorg Chem (2010) 15:841–850 845
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phosphorous atom are nonequivalent, owing to the differ-
ent mobility of the rings, and show signals in different
areas of the 1H NMR spectrum. The signals corresponding
to the more rotationally rigid ring are larger and shifted to
lower frequencies, owing to the almost parallel position of
the naphthalene rings.
The signals associated with the exchange-broadened
peaks of the less mobile ring are labeled with a prime in
‘‘Materials and methods.’’
Carbons belonging to different phenyl rings on the same
phosphorous atoms also exhibit different signals in the 13C
NMR spectrum; again, the signals corresponding to the
more rotationally rigid ring are larger. In particular, the
signal corresponding to C11
0 is tricky to recognize, both in
the 13C{1H} NMR spectrum and when using two-dimen-
sional techniques; it probably resonates in the 123–121-
ppm area. The different position of the phenyl rings, which
may result in different mobility, was already observed in
the X-ray structure of 1R [50].
The reactivity of the complexes under investigation was
compared by studying the solvolysis reaction in DMSO by
means of conductivity measurements and NMR spectros-
copy. Cisplatin underwent the Cl-/DMSO exchange with a
t1/2 of 2.9 h at 25 C and 1.2 h at 37 C. cis-[PtCl2(PPh3)2]
remained stable over 72 h at both 25 and 37 C, as did the
BINAP complexes. In contrast, the DABN complexes 2R
and 2S underwent rapid degradation when dissolved in
DMSO. This was verified via 195Pt NMR spectroscopy in
DMSO-d6. The unchanged complexes, 2R and 2S, exhibited
a chemical shift of -1,840 ppm. According to the literature
[51], the amine ligand, owing to its bulkiness, is rapidly
released and substituted with two DMSO molecules,
resulting in the cis-[PtCl2(DMSO)2] species (-3,448 ppm,
about 28%). A similar amount (about 23%) of the traditional
Cl-/DMSO exchanged complex was also detected at
-3,008 ppm. Surprisingly, the most abundant species in the
spectrum (about 41%) shows a signal at -2,958 ppm, cor-
responding to the [PtCl3(DMSO)]
- complex [52].
UV–vis spectroscopy and ESI–MS were used to evalu-
ate the solution behavior of the complexes in abiological
conditions (ultrapure water, or phosphate buffer pH 7.4, or
24 mM carbonate adjusted to pH 7.4) [53] over 24 h at
37 C with 1% cosolvent (DMSO for phosphane com-
plexes and ethanol for amine complexes).
The general trend in water with a cosolvent is approx-
imately the same for all the complexes. In particular, 94%
of cis-[PtCl2(PPh3)2], 67% of 1R and 2R, and 80% of 2R
and 2S remains intact (UV–vis spectroscopy). ESI–MS
confirmed the presence of the unchanged compound along
with some other species, the major one being the monoa-
quo complex. Furthermore, 2R and 2S showed traces of
other degradation products. Both phosphate and carbonate
remarkably speed up hydrolysis and degradation reactions.
The optical rotatory power of the complexes was
determined and compared with that of the corresponding
ligands. Upon coordination, the rotation direction was
maintained, and the angles of optical rotation increased.
Cytotoxicity tests
Table 1 shows the IC50 values obtained in the three cell
lines following 72-h exposure to the complexes under
investigation, compared with those obtained for three ref-
erence compounds, namely, cisplatin, oxaliplatin, and cis-
[PtCl2(PPh3)2].
Cisplatin was the only compound tested that showed a
significant difference in the antiproliferative effect between
ovarian and colorectal cells and, in fact, its low efficacy
against colon cancers is well known. The other compounds
appear to be equally potent in ovarian cells (including their
cisplatin-resistant variant) and colorectal cells. The com-
plexes containing phosphanes (namely, 1R and 1S) were
slightly less potent than those containing amines, but all of
them had a lower resistance factor (i.e., the ratio between
IC50 values for cisplatin-resistant A2780Cp8 and A2780
cells) in ovarian cells than cisplatin, indicating their ability
to circumvent acquired cisplatin resistance.
Interaction of the platinum complexes with
the G-quadruplex
22AG was folded in the G-quadruplex structure in the
presence of either Na? or K? (Fig. 2). Among the various
conformations of G-quadruplex structures described for
22AG [54], the antiparallel structure is believed to be
formed in solution with both cations [30]. This structure is
rather flexible because the hydrogen bonds between the
four guanines of the 50 external G-quartet can be transiently
disrupted [30]. Consequently, the guanines belonging to
this 50 external G-quartet, as well as the four free adenines
in the loop regions, can form platinum adducts on their N7
atoms.
The folded structure of 22AG was incubated overnight
with 3 equiv of the platinum complexes. The various pla-
tination products were then separated by gel electropho-
resis and isolated (Fig. 3).
The results show that the incubation of the G-quadru-
plex with all the platinum complexes leads to new products
that migrate more slowly than unreacted 22AG on gel
electrophoresis. This indicates platination of the G-quad-
ruplex structure of 22AG. Since the migration of oligonu-
cleotides depends on the number of platinum adducts, the
more slowly migrating products contain more than one
platinum complex.
The efficiency of platination (i.e., the amount of plati-
nated products) differs between the two pairs of isomeric
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complexes 1R and 1S and 2R and 2S, since the phosphane
derivatives 1R and 1S (5 and 10%, respectively) are less
reactive than the amine derivatives 2R and 2S (20 and
30%, respectively), likely because of the presence of two
additional phenyl groups that increase the overall bulkiness
of the ligands and the trans effect of the phosphorus atom
itself. However, in both isomer pairs, the R isomers interact
with 22AG less efficiently than their respective S
counterparts.
Since the target DNA is a chiral macromolecule, char-
acterized by a right-handed helical configuration [55, 56], it
can differentiate between these enantiomeric alkylating
agents. This assumption is confirmed in the case of oxa-
liplatin, namely, 1,2-diaminocyclohexane(ethanedioate-
O,O)platinum(II): in fact its three possible conformational
isomers [(R,R), (S,S), and (R,S), respectively] interact dif-
ferently with DNA. Kidani et al. [57] showed that the (R,R)
isomer was the most effective against cisplatin-sensitive
and cisplatin-resistant cancer cell lines, and this is the
isomer currently employed in chemotherapy [58]. Other
chiral complexes show different biological activity
depending on their isomeric form and affinity for DNA
[59–64].
Similarly, the stereochemical arrangement of the
organic ligand in these complexes plays a role in driving
the interaction between the platinum moiety and nucleo-
bases of the G-quadruplex structure of 22AG. Interestingly,
although there is no direct relationship between the anti-
proliferative effect of alkylating agents and their ability to
stabilize G-quadruplexes, the somewhat higher IC50 values
Table 1 IC50 values for 72-h continuous treatment of three different
human tumour cell lines (A2780 ovarian carcinoma and its cisplatin-
resistant variant A2780Cp8, and colon adenocarcinoma HCT116)
with compounds 1R, 1S, 2R, and 2S (see Fig. 1) and the reference
complexes cisplatin, oxaliplatin, and cis-[PtCl2(PPh3)2]
Compound IC50 (lM)
A2780
IC50 (lM)
A2780Cp8
Resistance factor IC50 (lM)
HCT116
Cisplatin 1.15 ± 0.09 14.99 ± 0.44* 13.03 10.98 ± 1.9**
Oxaliplatin 0.63 ± 0.11 0.55 ± 0.11 0.87 0.661 ± 0.035
cis-[PtCl2(PPh3)2] 20.98 ± 3.5 14.47 ± 2.14 0.69 21.83 ± 6.1
1R 13.82 ± 3.53 17.51 ± 0.9 1.27 16.75 ± 3.57
1S 7.77 ± 1.71 10.48 ± 0.74 1.35 10.32 ± 0.93
2R 1.36 ± 0.3 1.58 ± 0.51 1.16 0.98 ± 0.05
2S 1.15 ± 0.11 1.27 ± 0.35 1.10 1.61 ± 0.14
*P \ 0.001 versus A2780; **P \ 0.05 versus A2780
Fig. 2 Antiparallel
G-quadruplex structure of 22AG
(right) formed by the stacking
of three G-quartets (left). The
arrows indicate the potential
platination sites
Fig. 3 Electrophoresis gel after
platination of the quadruplex
structure of 22AG by the
platinum complexes cis-
[PtCl2(PPh3)2], 1R, 1S, 2R, and
2S
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obtained for the R isomers may be associated with their
lower efficiency in reacting with the target DNA.
Very recently, the first evidence that one enantiomer of a
supramolecular cylinder can selectively stabilize human
telomeric G-quadruplex structure was reported [65]. In
particular, the P enantiomer has a strong preference for
G-quadruplex over duplex DNA, and its selectivity has
been demonstrated also by telomere shortening in cancer
cells [66].
Platinum binding sites
The platinum binding sites were identified for the major
platinated products (noted with an asterisk in Fig. 3) as
follows:
1. cis-[PtCl2(PPh3)2] binds to A7 and A13. Since the
migration of this adduct is very slow compared with
that of the platination products of 1S, 1R, 2S, and 2R,
it can be surmised that each 22AG molecule binds two
platinum complexes, which therefore behave as mono-
functional electrophilic agents.
2. 1R and 1S preferentially coordinate A13.
3. 2R and 2S are mainly bound to G10 and A19.
The platination sites identified in all the experiments are
specific for platination of a G-quadruplex structure of
22AG rather than of its unfolded form, as only the adenines
in the loop regions (A7, A13, or A19) and/or some gua-
nines of the 50 external G-quartet (G10) are readily
accessible in such a structure. Moreover, the platination of
G10 suggests that the antiparallel structure was trapped
[29, 30]. Furthermore, when two platination sites were
identified, they lay at the opposite sides of the G-quadru-
plex structure, indicating that the complexes under study
acted as monofunctional, and not cross-linking, agents. In
contrast, cisplatin was able to cross-link the G-quadruplex
structure of 22AG, resulting mainly in A1–G10 and A13–
G22 chelates [29]. Moreover, the bulkiest platinum com-
plexes (1R, 1S, and cis-[PtCl2(PPh3)2]) platinated the same
sites on the G-quadruplex structure as the two monofunc-
tional platinum complexes containing a simple terpyridine
or a p-tolylterpyridine [39].
The platinum binding sites depend on the nature of the
ligand. In the phosphane series, platination only occurred
on adenines, whereas in the amine series it also involved
two guanines belonging to the 50 external G-quartet. This
difference in platination sites may be due to the bulkiness
of the platinum ligands. With bulky ligands, as observed in
the phosphane series, platination occurred on readily
accessible platination sites, i.e., the adenines (especially
A13 [30]); in contrast, amine ligands also allowed plati-
nation of some less accessible adenine or guanine residues.
Since 2R and 2S are able to platinate the G-quadruplex
structure of the telomeric sequence, their affinity for this
structure could be evaluated using melting temperature
experiments. The observation of the optical density at
295 nm allows the detection of the folding and unfolding of
the structure as a function of temperature. In the absence of
a G-quadruplex ligand, a variation of the optical density as
function of temperature that is characteristic of the folding
state of the structure is observed (melting temperature of
43 C, Fig. S2). In contrast, in the presence of 2S or 2R
Fig. 4 a The 35G4/13GG
system. The underlined bases
are the platination sites for 2S.
b Denaturing gel
electrophoresis of the kinetics of
platination of the 35G4/13GG
system by 2S with radiolabeled
13GG (B1) or 35G4 (B2).
c Concentration of the
remaining 35G4 (squares) or
13GG (diamonds) as a function
of time. d Logarithm of the ratio
of the remaining amount of
35G4 as a function of the
logarithm of the remaining
amount of 13GG at each time
point of the reaction for the
determination of the rate
constant ratio (k35G4/k13GG) of
the quadruplex versus duplex
DNA platination
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only a slight optical density decrease was observed when
increasing the temperature, suggesting that the G-quadru-
plex structure had been trapped, because high temperatures
cannot unfold it. Therefore, it was not possible to evaluate
the melting temperature of such compounds.
Affinity of the platinum complexes for the
G-quadruplex structures and comparison of the kinetics
of platination of double-stranded DNA
and G-quadruplex structures
Since 2S is able to platinate a G-quadruplex structure, its
affinity for this structure was compared with that for duplex
DNA by means of intramolecular platination competition
experiments. This technique, described elsewhere [31, 39],
allows comparison, in the same system, of the kinetic
constants of platination of a GG site involved in a duplex
DNA with a quadruplex structure. Briefly, this system
consists of a 35-nucleotide DNA strand (35G4) in which
the sequence of 22AG (responsible for the quadruplex
component) is flanked by a 13-nucleotide tail; the duplex
component is formed by the association of this tail with the
complementary 13-nucleotide DNA (13GG). In the
resulting system (35G4/13GG), two possible platination
sites are present on each DNA architecture: G10 and A19
on the quadruplex component and G6 and G7 on the duplex
component (Fig. 4).
In the case under investigation, platination of the
G-quadruplex domain occurred twice as fast as platination
of the double-stranded domain. This difference is of the
same order of magnitude as that observed for cisplatin.
Thus, replacement of the two amine groups of cisplatin by
a chiral aromatic ligand does not seem to improve the
selectivity of platinum complexes for G-quadruplex struc-
tures relative to that for duplex DNA.
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